<DOC>
	<DOC>NCT02043808</DOC>
	<brief_summary>The objective is to assess the safety and effectiveness of new dabigatran and warfarin patients diagnosed with NVAF in the US DoD population.</brief_summary>
	<brief_title>The Safety and Effectiveness of Warfarin and Dabigatran Prescribed in the Non-Valvular Atrial Fibrillation Population With DoD Healthcare Coverage</brief_title>
	<detailed_description>Study Design: Retrospective</detailed_description>
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Dabigatran</mesh_term>
	<mesh_term>Warfarin</mesh_term>
	<criteria>Inclusion criteria: Patients must be continuously enrolled in a health plan during the preindex period; Patients must have at least one inpatient, or one physician office visit, emergency room visit with a diagnosis of AF (ICD9CM diagnosis code: 427.31in any position) on the index date or during the preindex period; Patients must have a prescription for dabigatran or warfarin (this first prescription will be the index date); Patients must be treatment naive from all OAC use prior to first dabigatran or warfarin prescription; Aged 1889 on the index date; Exclusion criteria: Patients with valvular procedures related to the baseline AF diagnosis will be excluded; Patients with transient causes of AF such as hyperthyroidism, any cardiac surgery, pericarditis, mycoarditis, pulmonary embolism within 3 months prior to their first diagnosis of AF;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>